Update on TRAUMAKINE development
Faron Pharmaceuticals Oy (“Faron” or the “Company”) · U.S. Food and Drug Administration (FDA) approval of new HIBISCUS study protocol in patients with COVID-19 infection · Company seeking patent protection for the sequential use of IV interferon beta-1a and corticosteroids · Pipeline expansion into additional organ protection indications · CMC scale-up in progress Company announcement, 26 January 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces